PEA

PEA

Palmitoylethanolamide For Occasional and Minor Pain Support*

400 mg

90 Vegetarian Capsules ( SKU: 9331U )

Benefits

  • Offers a natural source of PEA from non-GMO safflower oil
  • Micronized for improved solubility and absorption
  • Includes 400 mg of PEA in each capsule, allowing for easy and clinically relevant amounts
  • Suitable for vegetarians and vegans

Feature Summary

Palmitoylethanolamide (PEA) is an endogenously lipid produced in microglia and mast cells. PEA is a type of fatty acid ethanolamine that helps maintain neurological health.*1,2 It may also help relieve occasional muscle pain due to overuse.*3,4

It is found in higher amounts in areas of the brain involved in nociception, and clinical trials have demonstrated broad effectiveness for the relief of occasional muscle pain due to overuse both alone and in combination with standard treatment.7,8,9 In addition, PEA may help support healthy endothelial function, normal intraocular pressure, and a healthy mood.10,11,12

Supplement Facts:

Dosage:

Suggested Usage: 1 capsule 1–3 times per day or as directed by a health care professional.

Warnings:

Consult your health care professional prior to use if you are pregnant, trying to become pregnant, breastfeeding, taking medication, have a medical condition, or anticipate surgery. Keep out of reach of children.

Allergens:

Contains no artificial colors, preservatives, or sweeteners; no dairy, sugar, wheat, gluten, yeast, soy, sesame, corn, egg, fish, shellfish, animal products, salt, tree nuts, or GMOs. Suitable for vegetarians/vegans. Sealed for your protection. Do not use if seal is broken. For freshness, store in a cool, dry place.

Contraindications

No known contraindications exist, though safety during pregnancy and lactation has not been established.13

Drug Interactions

Currently, there are no known drug interactions. PEA has been used in clinical trials by itself for occasional pain, as well as in conjunction with citalopram, pregabalin, gabapentin, amitriptyline, oxycodone, and duloxetine.

  1. Skaper, S.D., Facci, L., Barbierato, M., et al. (2015). Mol Neurobiol,, 52(2), 1034-42.
  2. Keppel Hesselink, J.M., & Kopsky, D.J. (2015). J Pain Res, 8, 729-34.
  3. Artukoglu, B.B., Beyer, C., Zuloff-Shani, A., et al. (2017). Pain Physician, 20(5), 353-62.
  4. Paladini, A., Fusco, M., Cenacchi, T., et al. (2016). Pain Physician, 19(2), 11-24.
  5. Rinne, P., Guillamat-Prats, R., Rami, M., et al. (2018). Arterioscler Thromb Vasc Biol, 38(11), 2562-75.
  6. Petrosino, S., & Di Marzo, V. (2017). Br J Pharmacol, 174(11), 1349-65. 
  7. Skaper, S.D. & Facci, L. (2012). Philosophical Transactions of the Royal Society of London Series B, Biol sci, 367(1607), 3312-25.
  8. Gatti, A., Lazzari, M., Gianfelice, V., et al. (2012). Pain Med, 13(9), 1121-30.
  9. Marini, I., Bartolucci, M.L., Bortolotti, F., et al. (2012). J Orofac Pain, 26(2), 99-104. 
  10. Strobbe, E., Cellini, M., Campos, E.C. (2013). nvestig Ophthalmol Vis Sci, 54(2), 968-73.
  11. Gagliano, C., Ortisi, E., Pulvirenti, L., et al. (2011). Investig Ophthalmol Vis Sci, 52(9), 6096-100.
  12. Ghazizadeh-Hashemi, M., Ghajar, A., Shalbafan, M.R., et al. (2018). J Affect Disord, 232, 127-33.
  13. Nestmann, E.R. (2016). Food Sci Nutr, 5(2), 292-309.